Physician profile
Rustambir Singh
NPI 1891310546
$717.07
in general payments reported to CMS, 2019-2025
18 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $35.71 · 2021: $18.58 · 2023: $89.82 · 2024: $292 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $662.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $130.52 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $97.78 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Gilead Sciences, INC. | $56.52 | 2023 | Biktarvy |
| Abbvie INC. | $54.33 | 2025 | |
| Pfizer INC. | $52.38 | 2024 | |
| Sanofi-Aventis U.S. LLC | $42.82 | 2024 | |
| Amgen INC. | $40.42 | 2023-2024 | Repatha, Otezla |
| Ultragenyx Pharmaceutical INC. | $35.71 | 2020 | |
| Phadia US INC. | $31.34 | 2024-2025 | Immunocap |
| Biomarin Pharmaceutical INC. | $24.84 | 2025 | Voxzogo 1.2mg |
| Bayer Healthcare Pharmaceuticals INC. | $21.47 | 2025 | |
| Scilex Pharmaceuticals INC. | $20.80 | 2024 | |
| Intra-Sana Laboratories | $20.21 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.84 | 2024 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.58 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $18.43 | 2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $17.22 | 2024 | Farxiga |
| Collegium Pharmaceutical, INC. | $13.86 | 2024 | Belbuca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rustambir Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.